CDKN2A and neoplasm: Additional driver mutations have been found to involve the neurofibromin 1 (NF1) and the KIT (1–2%) genes [8,9,10,11], while mutations associated with tumor development have been observed in the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene, a well-known cell cycle regulator [12].